[1]
Quan, M.L.; Pinto, D.J.P.; Smallheer, J.M.; Ewing, W.R.; Rossi, K.A.; Luettgen, J.M.; Seiffert, D.A.; Wexler, R.R. Factor XIa inhibitors as new anticoagulants. J. Med. Chem., 2018, 61(17), 7425-7447.
[http://dx.doi.org/10.1021/acs.jmedchem.8b00173] [PMID: 29775297]
[http://dx.doi.org/10.1021/acs.jmedchem.8b00173] [PMID: 29775297]
[2]
Gailani, D.; Renné, T. Intrinsic pathway of coagulation and arterial thrombosis. Arterioscler. Thromb. Vasc. Biol., 2007, 27(12), 2507-2513.
[http://dx.doi.org/10.1161/ATVBAHA.107.155952] [PMID: 17916770]
[http://dx.doi.org/10.1161/ATVBAHA.107.155952] [PMID: 17916770]
[3]
Hoffman, M. A cell-based model of coagulation and the role of factor VIIa. Blood Rev., 2003, 17(Suppl. 1), S1-S5.
[http://dx.doi.org/10.1016/S0268-960X(03)90000-2] [PMID: 14697207]
[http://dx.doi.org/10.1016/S0268-960X(03)90000-2] [PMID: 14697207]
[4]
Hsu, C.; Hutt, E.; Bloomfield, D.M.; Gailani, D.; Weitz, J.I.; Factor, X.I. Factor XI inhibition to uncouple thrombosis from hemostasis. J. Am. Coll. Cardiol., 2021, 78(6), 625-631.
[http://dx.doi.org/10.1016/j.jacc.2021.06.010] [PMID: 34353538]
[http://dx.doi.org/10.1016/j.jacc.2021.06.010] [PMID: 34353538]
[5]
Srivastava, P.; Gailani, D. The rebirth of the contact pathway: a new therapeutic target. Curr. Opin. Hematol., 2020, 27(5), 311-319.
[http://dx.doi.org/10.1097/MOH.0000000000000603] [PMID: 32740037]
[http://dx.doi.org/10.1097/MOH.0000000000000603] [PMID: 32740037]
[6]
Safouris, A.; Magoufis, G.; Tsivgoulis, G. Emerging agents for the treatment and prevention of stroke: Progress in clinical trials. Expert Opin. Investig. Drugs, 2021, 30(10), 1025-1035.
[http://dx.doi.org/10.1080/13543784.2021.1985463] [PMID: 34555978]
[http://dx.doi.org/10.1080/13543784.2021.1985463] [PMID: 34555978]
[7]
Al-Horani, R.A.; Afosah, D.K. Recent advances in the discovery and development of factor XI/XIa inhibitors. Med. Res. Rev., 2018, 38(6), 1974-2023.
[http://dx.doi.org/10.1002/med.21503] [PMID: 29727017]
[http://dx.doi.org/10.1002/med.21503] [PMID: 29727017]
[8]
Visser, M.; Heitmeier, S.; ten Cate, H.; Spronk, H.M.H. Role of factor XIa and plasma kallikrein in arterial and venous thrombosis. Thromb. Haemost., 2020, 120(6), 883-993.
[http://dx.doi.org/10.1055/s-0040-1710013] [PMID: 32375196]
[http://dx.doi.org/10.1055/s-0040-1710013] [PMID: 32375196]
[9]
Tillman, B.; Gailani, D. Inhibition of factors XI and XII for prevention of thrombosis induced by artificial surfaces. Semin. Thromb. Hemost., 2018, 44(1), 060-069.
[http://dx.doi.org/10.1055/s-0037-1603937] [PMID: 28898903]
[http://dx.doi.org/10.1055/s-0037-1603937] [PMID: 28898903]
[10]
Al-Horani, R.A. Factor XI(a) inhibitors for thrombosis: an updated patent review (2016-present). Expert Opin. Ther. Pat., 2020, 30(1), 39-55.
[http://dx.doi.org/10.1080/13543776.2020.1705783] [PMID: 31847619]
[http://dx.doi.org/10.1080/13543776.2020.1705783] [PMID: 31847619]
[11]
Al-Horani, R.A. Targeting factor XI(a) for anticoagulation therapy: a patent landscape. Pharm. Pat. Anal., 2020, 9(1), 3-5.
[http://dx.doi.org/10.4155/ppa-2020-0002] [PMID: 32057285]
[http://dx.doi.org/10.4155/ppa-2020-0002] [PMID: 32057285]
[12]
Afosah, D.K.; Ofori, E.; Mottamal, M.; Al-Horani, R.A. Factor IX(a) inhibitors: An updated patent review (2003-present). Expert Opin. Ther. Pat., 2022, 32(4), 381-400.
[http://dx.doi.org/10.1080/13543776.2022.2026926] [PMID: 34991418]
[http://dx.doi.org/10.1080/13543776.2022.2026926] [PMID: 34991418]
